NanoViricides, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended December 31, 2023 (the company’s fiscal second quarter); filed February 14, 2024. Financial statements are unaudited. NanoViricides is a clinical-stage antiviral drug developer with no product revenue to date.
Financial results and liquidity
| Metric | Three months ended Dec. 31, 2023 | Six months ended Dec. 31, 2023 | Comparable 2022 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research and development expense | $1.57 million | $3.04 million | $1.17 million / $2.28 million |
| General and administrative expense | $611,000 | $1.18 million | $663,000 / $1.17 million |
| Net loss | $2.11 million | $4.08 million | $1.75 million / $3.32 million |
| Basic and diluted loss per share | $0.18 | $0.35 | $0.15 / $0.29 |
| Cash used in operating activities | Not presented for quarter | $2.89 million | $2.43 million for six months |
At December 31, cash and cash equivalents were $5.25 million, current assets $5.32 million, current liabilities $951,000, total liabilities $951,000, and stockholders’ equity $12.45 million. Cash declined $2.90 million from June 30. The company reported no revenue or meaningful operating margin; profitability and revenue-based margins are not applicable.
Research and development costs rose year over year, primarily due to outside laboratory and clinical-trial costs. Six-month net loss increased by approximately $768,000. The company had an accumulated deficit of $135.16 million. A $1.5 million related-party milestone note was converted into Series A preferred shares in October; the associated approximately $49,800 accrued interest was forgiven. The company had not drawn on its CEO-provided $2 million line of credit at quarter-end.
Business, developments and outlook
- The lead program, NV-CoV-2 (active ingredient NV-387), is in a Phase 1a/1b trial in India sponsored by licensee and collaborator KMPL. The healthy-subject portion was reported completed in January 2024 with no adverse events; data analysis was pending. Recruitment for the COVID-patient portion had been challenging, and the company said it was evaluating sites and expected recruitment to begin.
- The company reported preclinical NV-387 activity against RSV and in a smallpox-emulating animal model. These findings are preclinical, not evidence of clinical efficacy. Management plans to pursue further development for COVID and RSV after the current trial, and may seek non-dilutive funding for poxvirus work. Shingles and other antiviral programs remain at earlier stages.
- Management believes cash on hand and the available line of credit can fund planned operations for at least 12 months from filing. It expects development and clinical-trial spending to increase and says additional capital will be needed for longer-term plans. Funding, partnerships and favorable financing terms are not assured.
- In February 2024, the CEO line of credit was extended to December 31, 2025. TheraCour also suspended the requirement to maintain a two-month invoice advance until the company raises sufficient capital. A February amendment deferred specified unearned COVID-license cash milestone payments until a defined revenue event and capped payments at 50% of recognized revenue; financing proceeds are excluded from that definition.
Risks, related parties and controls
- The company has no commercialized products or revenue, expects continuing losses, and depends on raising capital or securing collaborators. Management’s runway estimate is not a guarantee; clinical costs, timelines, funding access and trial outcomes may differ from expectations.
- TheraCour, owned by CEO and significant stockholder Anil Diwan, supplies licensed technology and development services. KMPL, which has Dr. Diwan as a passive investor and advisor, sponsors the India trial. These related-party arrangements include material payments and should be assessed for terms and oversight.
- Disclosure controls and procedures were concluded to be ineffective at December 31, 2023 due to a previously reported material weakness related to timeliness. A financial reporting controls committee and added review layers were implemented, but the weakness was not fully remediated.
- The filing reported no pending or threatened legal proceedings believed to have a material adverse effect and no off-balance-sheet arrangements during the six-month period.
Key facts for investors to verify
- Trial status, complete safety data, data-lock and analysis timing, and progress recruiting and treating COVID patients.
- Actual cash burn and clinical-development spending versus the stated runway; availability and terms of the undrawn, collateralized related-party credit line.
- Effect of the TheraCour amendment and advance suspension on cash obligations, and the continuing economics and governance of related-party agreements.
- Evidence supporting potential RSV and poxvirus development, including required licenses, regulatory steps, funding and clinical timelines.
- Progress in remediating the material weakness in disclosure controls and the accuracy and timeliness of future filings.